Cabergoline and Toremifene are each a small molecule rather than a peptide.
Same target, different schedules: Cabergoline twice a week; Toremifene daily.
| Comparison | Cabergoline Dostinex · Caber | Toremifene toremifene citrate · Fareston |
|---|---|---|
| How it works | How it works Prolactin is held down by dopamine. Cabergoline supplies a long-lasting dopamine signal. | How it works Toremifene has two separate actions, and only one of them is the point. |
| What it is | A prolactin drug whose label asks for an echocardiogram before the first dose. | A SERM with a boxed warning for a heart rhythm that can kill. |
| Status | FDA approvedFDA-approved | FDA approvedFDA-approved |
| Typical dose | 0.25–1 mg per dose | 60 mg per day |
| How often | Twice a week | Daily |
| Stays active | 63 to 69 hours | 3 to 7 days |
| Dose comes from | FDA drug label | FDA drug label |
| Cycled? | Continuous, with the dose reassessed rather than paused FDA drug label | Continuous, until the disease progresses FDA drug label |
| What it does | ||
| Drug class | Ergot dopamine agonist (oral, not a peptide) | SERM (oral, not a peptide) |
| Used for | A prescription drug that lowers prolactin. On the research market it is used during a cycle, and for its effect on libido. | A tamoxifen alternative sold on the research market for gynecomastia and post-cycle use, with a heart rhythm warning tamoxifen does not carry. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | 0.25 up to 1 mg per dose, twice a week | 60 mg per day |
| Why that cycle | The label says to use the lowest effective dose and to reassess periodically whether treatment should continue, and to check prolactin after stopping to see whether it needs restarting. That is dose management rather than cycling. The valve monitoring interval of 6 to 12 months applies for as long as it is taken. | The label runs it daily with no planned break and no defined stopping point other than disease progression. Nothing studies the short courses it is sold for. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | By mouth (oral) | By mouth (oral) |
| Do not use if | Any existing heart valve disease, including valve leaflet thickening seen on an echocardiogram A history of pericardial, pleural, pulmonary or retroperitoneal fibrosis Uncontrolled high blood pressure Known hypersensitivity to ergot derivatives Suppressing milk production after birth, which the label advises against | Congenital or acquired long QT syndrome Uncorrected low potassium or low magnesium Taking any other drug that prolongs the QT interval Taking a strong CYP3A4 inhibitor, and grapefruit juice should also be avoided Pregnancy Banned in drug-tested sport |
What people actually report
Cabergoline
- The label asks for an echocardiogram before the first dose, and every 6 to 12 months after it, to look for heart valve damage.
- Existing valve disease is a contraindication, not a caution.
- It is an ergot derivative, and fibrosis of the heart, lungs, chest lining and abdomen have all been reported.
- Compulsive behavior including gambling and hypersexuality is a documented class effect of dopamine agonists.
Stop and get help if
- Shortness of breath, difficulty breathing when lying flat, or swelling in the legs
- Chest pain, or a persistent cough
Toremifene
- It carries a boxed warning for QT prolongation, which can lead to torsades de pointes and to fainting, seizure or death.
- The effect gets larger as the dose and the blood level go up.
- The label requires low potassium or low magnesium to be corrected before starting, and monitored afterward.
- Banned in drug-tested sport at all times.
Stop and get help if
- Fainting, near-fainting, or a racing or pounding heartbeat
- A seizure
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.